Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed |
|---|---|---|
|
Adagio Medical Holdings, Inc.
13G/A
Amendment 1
ADGM · 00534B100
|
3.2% |
7/28/2026
Event 6/30/2026
|
|
PMV Pharmaceuticals, Inc.
13G/A
Amendment 4
PMVP · 69353Y103
|
4.9% |
7/28/2026
Event 6/30/2026
|
|
Serina Therapeutics, Inc.
13G
SER · 81751A108
|
6.7% |
5/4/2026
Event 3/31/2026
|
|
Anteris Technologies Global Corp.
13G/A
Amendment 3
AVR · 03675P102
|
5.5% |
5/4/2026
Event 3/31/2026
|
|
PMV Pharmaceuticals, Inc.
13G/A
Amendment 3
PMVP · 69353Y103
|
5.8% |
5/4/2026
Event 3/31/2026
|
|
Adagio Medical Holdings, Inc.
13G
ADGM · 00534B100
|
6.1% |
2/11/2026
Event 12/31/2025
|
|
Aligos Therapeutics, Inc.
13G/A
Amendment 1
ALGS · 01626L204
|
5.5% |
2/11/2026
Event 12/31/2025
|
|
PMV Pharmaceuticals, Inc.
13G/A
Amendment 2
PMVP · 69353Y103
|
4.98% |
11/12/2025
Event 9/30/2025
|
|
NeuroOne Medical Technologies Corp
13G/A
Amendment 1
NMTC · 64130M209
|
4.7% |
11/12/2025
Event 9/30/2025
|
|
Bright Minds Biosciences Inc.
13G/A
Amendment 2
DRUG · 10919W405
|
2.7% |
11/12/2025
Event 9/30/2025
|
|
Aprea Therapeutics, Inc.
13G/A
Amendment 4
APRE · 03836J201
|
1.9% |
11/12/2025
Event 9/30/2025
|
|
Anteris Technologies Global Corp.
13G/A
Amendment 2
AVR · 03675P102
|
4.9% |
11/12/2025
Event 9/30/2025
|
|
NeuroOne Medical Technologies Corp
13G
NMTC · 64130M209
|
7.1% |
8/13/2025
Event 6/30/2025
|
|
Bright Minds Biosciences Inc.
13G/A
Amendment 1
DRUG · 10919W405
|
7.3% |
8/13/2025
Event 6/30/2025
|
|
PMV Pharmaceuticals, Inc.
13G/A
Amendment 1
PMVP · 69353Y103
|
7.2% |
8/13/2025
Event 6/30/2025
|
|
Aprea Therapeutics, Inc.
13G/A
Amendment 3
APRE · 03836J201
|
5.1% |
8/13/2025
Event 6/30/2025
|
|
Anteris Technologies Global Corp.
13G/A
Amendment 1
AVR · 03675P102
|
8.1% |
8/13/2025
Event 6/30/2025
|
|
Aligos Therapeutics, Inc.
13G
ALGS · 01626L204
|
5.5% |
8/13/2025
Event 6/30/2025
|
|
Ventyx Biosciences, Inc.
13G/A
Amendment 1
VTYX · 92332V107
|
3.6% |
4/8/2025
Event 3/31/2025
|
|
Vaxart, Inc.
13G
VXRT · 92243A200
|
2.5% |
4/8/2025
Event 3/31/2025
|
|
Q32 Bio Inc.
13G
QTTB · 746964105
|
0% |
4/8/2025
Event 3/31/2025
|
|
PMV Pharmaceuticals, Inc.
13G
PMVP · 69353Y103
|
7.2% |
4/8/2025
Event 3/31/2025
|
|
Bright Minds Biosciences Inc.
13G
DRUG · 10919W405
|
7.2% |
4/8/2025
Event 3/31/2025
|
|
Aprea Therapeutics, Inc.
13G/A
Amendment 2
APRE · 03836J201
|
5.0% |
4/8/2025
Event 3/31/2025
|
|
Anteris Technologies Global Corp.
13G
AVR · 03675P102
|
9.6% |
4/8/2025
Event 3/31/2025
|
|
Ventyx Biosciences, Inc.
13G
VTYX · 92332V107
|
5.7% |
2/10/2025
Event 12/31/2024
|
|
Vaxart, Inc.
13G
VXRT · 92243A200
|
5.1% |
2/10/2025
Event 12/31/2024
|
|
PMV Pharmaceuticals, Inc.
13G
PMVP · 69353Y103
|
6.9% |
2/10/2025
Event 12/31/2024
|
|
Q32 Bio Inc.
13G
QTTB · 746964105
|
5.7% |
2/10/2025
Event 12/31/2024
|
|
Anteris Technologies Global Corp.
13G
AVR · 03675P102
|
9.6% |
2/10/2025
Event 12/31/2024
|
|
Modular Medical, Inc.
13G/A
Amendment 2
MODD · 60785L207
|
0.7% |
2/10/2025
Event 12/31/2024
|
|
Aprea Therapeutics, Inc.
13G/A
Amendment 1
APRE · 03836J102
|
5.1% |
2/10/2025
Event 12/31/2024
|
|
Bright Minds Biosciences Inc.
13G
DRUG · 10919W405
|
6.5% |
2/10/2025
Event 12/31/2024
|